127 Determinants for side effects 4 Outcomes Neurobehavioral problems Sleep problems No clinically significant problems No n = 35 Yes n = 70 No n = 43 Yes n = 61 n = 27 5.8 (4.3-13.1) 5.3 (4.0-8.4) 5.5 (4.0-9.8) 5.3 (4.1-8.4) 5.4 (4.0-12.1) 23 (65.7) 41 (58.6) 28 (65.1) 35 (57.4) 17 (63) 12 (34.3) 29 (41.4) 15 (34.9) 26 (42.6) 10 (37) 37 (27-43) 33 (21-44) 33 (22-43) 37 (28-48) 34 (25-43) 32 (91.4) 61 (87.1) 37 (86.0) 56 (91.8) 25 (92.6) 3 (8.6) 9 (12.9) 6 (14.0) 5 (8.2) 2 (7.4) 30 (85.7) 63 (90) 39 (90.7) 53 (86.9) 24 (88.9) 4 (11.4) 7 (10) 3 (7.0) 8 (13.1) 2 (7.4) 27 (77.1) 58 (82.9) 35 (81.4) 49 (80.3) 20 (74.1) 8 (22.9) 12 (17.1) 8 (18.6) 12 (19.7) 7 (25.9) Abbreviations: ALL: acute lymphoblastic leukemia, BPDCN: blastic plasmacytoid dendritic cell neoplasm, CNS: central nervous system, IQR: interquartile range, MRG: medium risk group, TLP: traumatic lumbar puncture. No problems 27 Sleep problems 53 17 8 Figure 4. Venn diagram of dexamethasone-induced neurobehavioral and sleep problems Neurobehavioral problems were reported in 70 patients, sleep problems in 61 patients. In 27 patients, no clinically relevant problems were reported.
RkJQdWJsaXNoZXIy MTk4NDMw